Wearable device-based intervention was associated with overall improved physical activity and dyspnea after lung cancer ...

A team at Northwestern is the first to perform a transplantation of both lungs and the liver on a patient with advanced lung ...

Surviving lung cancer in Aotearoa New Zealand could depend on whether you can access a GP—raising questions about equity in ...

The statistics are grim, but there’s a reason why lung cancer often progresses past the point where it’s treatable: Early ...

Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...

A new report has revealed the devastating number of women who are dying prematurely of lung disease in one part of Merseyside ...

Sep. 25, 2024 — Researchers have tested a combination of treatments in mice with lung cancer and shown that these allow immunotherapies to target non-responsive ... Experimental mRNA Cancer ...

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

Experts at CHEST 2024 highlighted significant racial disparities in lung cancer screening, treatment, and outcomes, ...

Lung cancer is the most common cancer that occurs when cells in the lungs tend to divide uncontrollably, causing tumours. The ...

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...